Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
Public ClinicalTrials.gov record NCT02204553. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Expanded Treatment Protocol of Panobinostat (LBH589) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma Who Have Had at Least One Prior Line of Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This will be a multi-center, open label, expanded treatment protocol of panobinostat, bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma. Panobinostat will be administered at a starting dose of 20mg orally three times a week (every other day) for two weeks on and one week off, with dose adjustments permitted based on observed toxicity. Bortezomib will be administered either intravenously or sub-cutaneously, twice a week on days 1 and 4, two weeks on 1 week off. After 8 cycles of treatment, patients who have achieved stable disease or better by modified EBMT 1998 criteria may continue combination therapy with bortezomib dosing changed to days 1 and 8 of a 21 day cycle for up to 48 weeks of therapy. At the end of the treatment period, (48 weeks) patients with stable disease or better may continue on therapy at the discretion of their investigator until September 2015 or until drug is commercially available, whichever comes first. Patients who have not achieved at least stable disease by 8 cycles must discontinue from study treatment. Dexamethasone will be administered on the day of and the day immediately following bortezomib treatment. Patients will not receive any study treatment during the third week of each cycle. Cycles will be defined as 21 days of treatment. Investigators may not add any other anti-myeloma agents (with the exception of bisphosphonates) while patients remain on study treatment. Patients will remain on study until disease progression, unacceptable toxicity, or end of the study
Study identification
- NCT ID
- NCT02204553
- Recruitment status
- No Longer Available
- Study type
- Expanded access
- Phase
- Not listed
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Not listed
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 4, 2016
United States locations
- U.S. sites
- 27
- U.S. states
- 21
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Centers Ironwood Cancer | Chandler | Arizona | 85224 | — |
| Highlands Oncology Group Dept of Highlands Oncology Grp | Fayetteville | Arkansas | 72703 | — |
| Kaiser Permanente Medical Group Kaiser Permanente-Moanalua M.C | Anaheim | California | 92807 | — |
| Alta Bates Cancer Center | Berkeley | California | 94704 | — |
| Los Angeles Hematology/Oncology Medical Group | Los Angeles | California | 90017 | — |
| Stanford Cancer Center Stanford Cancer Institute (2) | Stanford | California | 94305 | — |
| George Washington U Medical Center Medical Faculty Associates | Washington D.C. | District of Columbia | 20037 | — |
| University Cancer Institute Univ. Cancer Institute | Boyton Beach | Florida | 33426 | — |
| Memorial Cancer Institute Memorial Cancer Inst. | Hollywod | Florida | 33021 | — |
| Lakes Research SC | Miami Lakes | Florida | 33014 | — |
| Emory University School of Medicine/Winship Cancer Institute Winship Cancer Institute (2) | Atlanta | Georgia | 30322 | — |
| Stormont-Vail Cancer Center | Topeka | Kansas | 66606 | — |
| Hematology Oncology Clinic Hematology Oncology Clinic | Baton Rouge | Louisiana | 70808 | — |
| Sinai Hospital of Baltimore Sinai Hospital, Baltimore | Baltimore | Maryland | 21215 | — |
| Bronson Battle Creek Cancer Care Center | Battle Creek | Michigan | 49017 | — |
| University of Mississippi Medical Center Cancer Institute | Jackson | Mississippi | 39216-9941 | — |
| Research Medical Center Research Med. Center | Kansas City | Missouri | 64132 | — |
| Oncology Hematology West, PC Nebraska Cancer Specialists | Omaha | Nebraska | 68124 | — |
| Hematology Oncology of Central New Jersey | Little Silver | New Jersey | 07739 | — |
| Morton Coleman, MD M. Coleman, MD (2) | New York | New York | 10021 | — |
| Cancer Centers of the Carolinas GHS Cancer Institute | Greenville | South Carolina | 29615 | — |
| Wellmont Medical Associates | Bristol | Tennessee | 37620 | — |
| Texas Oncology Texas Oncology - Arlington | Dallas | Texas | 75251 | — |
| Texas Oncology TX Oncology Baylor | Dallas | Texas | 75251 | — |
| Northern Utah Cancer Associates SC | Ogden | Utah | 84403-3105 | — |
| Virginia Oncology Associates Virginia Oncology Assoc. (2) | Norfolk | Virginia | 23502 | — |
| Fox Valley Hematology and Oncology | Appleton | Wisconsin | 54915 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02204553, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2016 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02204553 live on ClinicalTrials.gov.